Status History
2026-07-28
OPEN → INELIGIBLE
· The programme is for biotech startups, but the applicant is an independent researcher, not a startup company. Additionally, the funding sources discussed (BARDA, CDMRP) require U.S. health security focus and typically U.S.-based entities or partnerships, which the applicant (Nigerian, based in Germany) does not meet.